|
Notification of cessation of securities - NTI
|
30 June 2023 at 5:35pm
|
|
Notification regarding unquoted securities - NTI
|
28 June 2023 at 4:35pm
|
|
NTI to Present at Rett Syndrome Foundation Meeting
|
5 June 2023 at 8:55am
|
|
Results of Meeting
|
1 June 2023 at 7:15pm
|
|
NTI Granted 2 Year Extension of Treatment for ASD Patients
|
31 May 2023 at 9:50am
|
|
NTI granted HREC Approval for PANDAS/PANS Trial Extension
|
30 May 2023 at 9:50am
|
|
Notification of cessation of securities - NTI
|
16 May 2023 at 5:10pm
|
|
NTI Completes Recruitment in PANDAS/PANS Clinical Trial
|
3 May 2023 at 9:40am
|
|
Proposed issue of securities - NTI
|
1 May 2023 at 5:10pm
|
|
Notification of cessation of securities - NTI
|
1 May 2023 at 5:10pm
|
|
Notice of General Meeting/Proxy Form
|
1 May 2023 at 4:55pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
27 April 2023 at 9:35am
|
|
Notice of Quarterly Investor Conference Call
|
26 April 2023 at 9:15am
|
|
Neurotech to Present at NWR Virtual Healthcare Conference
|
20 March 2023 at 11:45am
|
|
Investor Presentation
|
20 March 2023 at 10:20am
|
|
NTI to Launch Phase II Clinical Trial in Rett Syndrome
|
20 March 2023 at 9:25am
|
|
Investor Conference Call - 52 Week Autism Study Results
|
17 March 2023 at 10:30am
|
|
Investor Presentation
|
17 March 2023 at 10:20am
|
|
Phase I/II ASD Clinical Trials Results at 52 Weeks
|
17 March 2023 at 10:15am
|
|
Trading Halt
|
15 March 2023 at 10:10am
|
|
Notification of cessation of securities - NTI
|
1 March 2023 at 8:15pm
|
|
Notification regarding unquoted securities - NTI
|
28 February 2023 at 8:25pm
|
|
Appendix 4D and Half Year Accounts
|
28 February 2023 at 5:20pm
|
|
First Patient Treated in Phase I/II PANDAS/PANS Trial
|
16 February 2023 at 11:55am
|
|
Approval for Additional Phase I/II ASD Trial Extension
|
14 February 2023 at 10:35am
|
|
Secondary Trading Notice
|
31 January 2023 at 7:35pm
|
|
Application for quotation of securities - NTI
|
31 January 2023 at 7:05pm
|
|
Top 20 securityholders
|
31 January 2023 at 6:59pm
|
|
Distribution Schedule
|
31 January 2023 at 6:59pm
|
|
Application for quotation of securities - NTI
|
31 January 2023 at 6:55pm
|
|
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 January 2023 at 10:10am
|
|
HREC Approval for Phase I/II PANDAS/PANS Clinical Trial
|
27 January 2023 at 9:55am
|
|
Secondary Trading Notice
|
24 January 2023 at 7:30pm
|
|
Application for quotation of securities - NTI
|
24 January 2023 at 7:20pm
|
|
Notice of Quarterly Investor Conference Call
|
24 January 2023 at 7:10pm
|
|
NTI Granted FDA Pre-IND Meeting for NTI164 in ASD
|
19 January 2023 at 11:55am
|
|
Extension of Offers under Prospectus
|
13 January 2023 at 2:20pm
|
|
Change of Director's Interest Notice x2
|
28 December 2022 at 8:25pm
|
|
Notification regarding unquoted securities - NTI
|
23 December 2022 at 7:40pm
|
|
Application for quotation of securities - NTI
|
23 December 2022 at 5:00pm
|
|
Proposed issue of securities - NTI
|
22 December 2022 at 8:35pm
|
|
Target Market Determination - Option Offer
|
22 December 2022 at 7:50pm
|
|
Disclosure Document
|
22 December 2022 at 7:50pm
|
|
Application for quotation of securities - NTI
|
21 December 2022 at 8:10pm
|
|
Final Director's Interest Notice
|
21 December 2022 at 6:59pm
|
|
Passing of a Director
|
21 December 2022 at 10:35am
|
|
Commencement of Phase II/III ASD Clinical Trial
|
19 December 2022 at 1:30pm
|
|
Results of Meeting
|
30 November 2022 at 8:15pm
|
|
2022 Annual General Meeting Presentation
|
30 November 2022 at 6:30pm
|
|
Chairman Address to 2022 Annual General Meeting
|
30 November 2022 at 6:25pm
|
Neurotech International